Cholecalciferol Supplementation in Critically Ill Patients With Severe Vitamin D Deficiency.
NCT ID: NCT02868827
Last Updated: 2020-06-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE2/PHASE3
Total Enrollment
127 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-08-27
Study Completion Date
2019-11-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of the research study is to determine whether a single high dose of vitamin D is helpful in reducing critical illness related complications in intensive care patients who are having sever vitamin D deficiency.
Vitamin D deficiency is quite common in critically ill patients ranging from 81.5% to 99%. A number of scientific studies have documented a strong correlation between low levels of vit.D and increased rate of adverse outcomes including infection, acute kidney injury and mortality in ICU patients. A recent randomized controlled trial (RCT) has demonstrated a 50% reduction in hospital mortality in severe vit.D deficient patients following a single high dose of cholecalciferol (Vitamin D3). However, the role of Vit.D supplementation to boost up host immune system and eventually reduction of mortality has yet to be determined by large randomized controlled trials in humans. Hence the study aims to run a randomized controlled trial (RCT) in order to study the role of Vitamin D in critically ill patients.
Vitamin D deficiency is quite common in critically ill patients ranging from 81.5% to 99%. A number of scientific studies have documented a strong correlation between low levels of vit.D and increased rate of adverse outcomes including infection, acute kidney injury and mortality in ICU patients. A recent randomized controlled trial (RCT) has demonstrated a 50% reduction in hospital mortality in severe vit.D deficient patients following a single high dose of cholecalciferol (Vitamin D3). However, the role of Vit.D supplementation to boost up host immune system and eventually reduction of mortality has yet to be determined by large randomized controlled trials in humans. Hence the study aims to run a randomized controlled trial (RCT) in order to study the role of Vitamin D in critically ill patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Enteral Supplement Vitamin D Incritically Ill Patients
NCT04292873
Vitamin D Deficiency
Critical Illness
COMPLETED
NA
Hypovitaminosis D in Neurocritical Patients
NCT02881957
Craniocerebral Trauma
Intracranial Aneurysm
Brain Neoplasms
+7 more
COMPLETED
PHASE2/PHASE3
Vitamin D to Improve Outcomes by Leveraging Early Treatment
NCT03096314
Acute Respiratory Distress Syndrome
Vitamin D Deficiency
Critical Illness
COMPLETED
PHASE3
Vitamin D Supplementation in Intensive Care Unit Patients
NCT04915963
Dietary Supplements
Intensive Care Unit
Vitamin D Deficiency
+1 more
COMPLETED
PHASE3
The Association of Vitamin D Supplementation With the Outcome in Critically Ill Children
NCT04536831
Critically Ill
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
DETAILED DESCRIPTION
Introduction: Vitamin D is a fat soluble vitamin and it affects multiple systems of our body. It not only plays a key role in musculoskeletal system but also works on our immune and cardiovascular systems. Because of its wide range of anti-inflammatory and metabolic properties, vitamin D, recently, has gained an immense importance among the intensivists.
Most of the critically ill patients have vitamin D deficiency and are at high risk of complications ranging from systemic inflammatory response syndrome (SIRS), sepsis, septic shock, multi-organ dysfunction, multi-organ failure and finally death. Immune system dysregulation has been thought to play a pivotal role in the development of sepsis. Onset and progression of sepsis are dependent upon a fine balance between pro-inflammatory and anti-inflammatory mediators of the immune system. Massive and uncontrolled release of pro-inflammatory cytokines leads to widespread tissue damage and multi-organ failure. It has been found that the cells of the immune system (both innate and acquired) express receptors for vitamin D. Low levels of it renders the immune system regulatory cells dysfunctional and in turn, increases the risk of infections and other adverse outcomes. It has been estimated that even with optimal treatment anywhere from 16% to more than 80% of patients with sepsis don't survive.
To improve the survival of critically ill patients, several research studies have been focused on the identification of various biomarkers and their correlation with disease severity. Timely supplementation of cholecalciferol has been demonstrated as one of the mortality reduction interventions. In recent studies, vitamin D has been identified as an important regulator of our immune system and its deficiency is quite common in ICU patients ranging from 81.5% to 99%.
A number of scientific studies have documented a strong correlation between low levels of vit.D and increased rate of adverse outcomes including infection with multi drug resistant organisms, acute kidney injury, decreased left ventricular ejection fraction and mortality in ICU patients. It has been found that the emergence of acinetobacter baumannii infections in significantly more common in vit D deficient critically ill patients and vit D deficiency is an independent risk factor for the development of Acinetobacter baumannii infections in intensive care unit.
A recent RCT has demonstrated 50% reduction in hospital mortality in patients with severe vit.D deficiency following a single high dose of cholecalciferol (Vitamin D3). However, the role of Vit.D supplementation to boost up host immune system and eventually reduction of mortality has yet to be determined by large randomized controlled trials.
In patients with severe vitamin D deficiency, gastrointestinal absorption of vit.D, after enteral supplementation could be variable depending upon the patient's gastrointestinal functions, critical illness and the activity of hepatic cytochrome P 450 system. In order to restore optimal vit.D level in critically ill patients (possibly within first 48 hours), a single high dose of it has been suggested on admission to ICU. As in critically ill patients, it is highly unlikely to restore Vitamin D within a reasonable period of time by supplementing 400-4000 international units/day (recommended daily allowance). Moreover, a single large dose of vit.D through the enteral route is highly unlikely to cause vit.D toxicity. The acutely toxic level of vit.D is considered to be more than 150 ng/ml. Furthermore, this high loading dose of cholecalciferol has been justified based on the safety findings of previous studies.
In addition, during a pilot study followed by a large randomized controlled trial conducted by Karen A et al, no serious adverse events were noted with a single high dose (540,000 I.U) of cholecalciferol. The highest 25-hydroxyvitamin D level measured was 107 ng/ml which is far below the currently suggested toxic level of vit.D (that is more than 150 ng/ml). Moreover, one patient in vitamin D3 group was found to have a total serum calcium level of 12 mg/dl and an ionized serum calcium level of 6 mg/dl but that patient had primary hyperparathyroidism (although normocalcemic at study inclusion). However, the incidence of falls and fracture was similar in vitamin D3 and placebo groups for a follow-up period of six months. So a single high dose of cholecalciferol is less likely to increase the incidence of hypocalcemia, hypercalciuria, falls and fractures which have been found to be increased with annual high doses of vitamin D3.
Hence the investigator intends to use a single high dose of cholecalciferol in order to restore it deficiency quickly, hopefully within 1 to 2 days in order to give maximum benefits to our critically ill patients right from the start of their illness.
The aim of our RCT is to study the role of Vit.D supplementation in critically ill patients. By boosting up the already struggling immune system of critically ill patients, the investigator assumes a significant reduction in mortality and other adverse outcomes.
Hypothesis: A single high dose of cholecalciferol supplementation improves survival in critically ill patients with severe vitamin D deficiency.
Null Hypothesis: A single high dose of Cholecalciferol supplementation in critically ill patients will not reduce the mortality and adverse outcomes.
Recruitment and randomization: Patients or their surrogates will be contacted on admission to ICU and study information will be provided to them by the research staff members. Consented patients will be randomized. Randomization list will be prepared by King Abdullah Medical City (KAMC) research center. The list will be used to prepare sealed envelopes each containing the assigned treatment. These envelopes will be stored in the pharmacy and opened up by the research pharmacist who will prepare medication/placebo for the randomized patients.
Blinding: Blinding will be done by research pharmacist in KAMC pharmacy. Fresh milk will be used as a placebo. The study medication (a white-colored, powdered form of cellulose based vit.D) will be dissolved in fresh milk so that both interventional drug and placebo will have the same color, odor, consistency, taste, and amount as that of interventional medication.
For all vit. D deficient patients, supplement 50,000 IU of cholecalciferol per week through the enteral route as a part of routine ICU treatment plan. As our recruited patients will be having severe vitamin D deficiency (Vit. D level below 12ng/ml) so both interventional and placebo group patients will receive our routine treatment for vit.D deficiency which is 50,000 IU of cholecalciferol through enteral route per week.
Intervention: Patients randomized to vitamin D group will receive 400,000 IU of cholecalciferol dissolved in 45 ml of fresh milk through orogastric tube/nasogastric tube/Oral within 1st 24 hours of ICU admission. This high dose is in addition to our routine treatment for vitamin D deficiency.
Post-recruitment retention strategies: the study will follow our patients for 30 days or as long as they stay in ICU after supplementation of a single high dose of vitamin D or placebo. As the investigators are working with critically ill patients, expecting at least a few weeks of hospital stay. However, the patient having early and quick recovery will be discharged home and will be followed up by one of the assigned research team members who will be contacting them by phone and inquire about any complications related to the research study.
Method: the investigator will complete a randomized controlled trial by supplementing cholecalciferol 400,000 IU versus placebo within 24 hours of ICU admission that would be added to our routine treatment for vit.D deficiency. Safety of this high dose of vit D has been validated in previous studies. This trial will employ block randomization and intention to treat protocol. This single-center study would be completed over a period of 2 complete years here in KAMC Intensive care Unit.
Laboratory Measurements: Blood samples will be obtained at baseline (day 0) and days 1, 3, 7, and 28 to assess serum parathyroid hormone, total and bioavailable 25-hydroxyvitamin D levels, phosphate, procalcitonin, leukocytic count, hemoglobin, creatinine, bilirubin, beta natriuretic peptide (BNP), blood glucose and albumin levels. In addition, the investigator will also measure urinary calcium and urinary creatinine levels
Data Collection: Patients will be followed up (1 month) closely for the development of study-drug related complications if any, for example, hypercalcemia, hypercalciuria, fractures, etc. Data elements to be collected will include, but not limited to:
1. \- Date and time of admission to hospital
2. \- Mode of admission (Emergency Room or in-patients)
3. \- Date and time of ICU admission
4. \- 25 - hydroxyl vitamin D level on admission to ICU.
5. \- Sequential Organ Failure Assessment (SOFA) score
6. \- Acute Physiology And Chronic Health Index (APACHI) Score 7-Patient's co-morbidities (Diabetes, Hypertension, Chronic kidney disease, Chronic obstructive pulmonary disease, Ischemic Heart Disease, Coronary Artery Bypass Grafting, Cerebrovascular accident, Arrhythmias, Anemias, smoking, obesity, cancer)
8 - Mode of Oxygen delivery to the patient 9 - Previous positive cultures and antibiotic therapy within the last 3 months 10 - Empirical antibiotic therapy on admission to hospital and ICU 11 - Baseline clinically relevant investigation, for example, Echo, Electrocardiography, Ultrasound Doppler for Deep venous thrombosis, CT brain/chest/abdomen, 12 - Endo/bronchoscopic findings if any 13 - Vasopressors and ionotropic support duration 14 - Central venous catheter, arterial line, pigtail, chest tube (site, date and time of insertion) 15 - Evidence of acute or acute on chronic kidney injury on admission to ICU. 16 - Surgeries - previous and recent surgeries and any post-op complications 17 - Previous immunosuppressive therapies for example chemo/radio/glucocorticoid therapy.
Sample size calculation: A recent RCT demonstrated almost 50% reduction in hospital mortality (46.1% in placebo versus 28.6% in Vit D group) by supplementing 540,000 IU of Vit D3 to critically ill patients having severe vitamin D deficiency (25-hydroxyvitamin D level ≤ 12 ng/ml). With an alpha = 5% (two tailed test), power = 95%, baseline mortality control group 30% and test group mortality 15%, the sample size required would be 195 patients per group. To account for losses to follow up of around 10%, the study aims to recruit 215 patients in each group. So the total number of patients required for both the groups would be 430 in 2 full years.
Statistical Analysis: the investigator will use an intention to treat approach to avoid the effects of crossover and dropout. Standard statistical analysis will include normally or near normally distributed variables reported as means and non-normally distributed variables as medians. Means will be compared by using student's t-test and medians by using Mann-Whitney U test. Differences in proportions among categorical data will be assessed using Fisher's exact test. A p-value of less than 0.05 will be considered to represent statistical significance for all comparisons.
Introduction: Vitamin D is a fat soluble vitamin and it affects multiple systems of our body. It not only plays a key role in musculoskeletal system but also works on our immune and cardiovascular systems. Because of its wide range of anti-inflammatory and metabolic properties, vitamin D, recently, has gained an immense importance among the intensivists.
Most of the critically ill patients have vitamin D deficiency and are at high risk of complications ranging from systemic inflammatory response syndrome (SIRS), sepsis, septic shock, multi-organ dysfunction, multi-organ failure and finally death. Immune system dysregulation has been thought to play a pivotal role in the development of sepsis. Onset and progression of sepsis are dependent upon a fine balance between pro-inflammatory and anti-inflammatory mediators of the immune system. Massive and uncontrolled release of pro-inflammatory cytokines leads to widespread tissue damage and multi-organ failure. It has been found that the cells of the immune system (both innate and acquired) express receptors for vitamin D. Low levels of it renders the immune system regulatory cells dysfunctional and in turn, increases the risk of infections and other adverse outcomes. It has been estimated that even with optimal treatment anywhere from 16% to more than 80% of patients with sepsis don't survive.
To improve the survival of critically ill patients, several research studies have been focused on the identification of various biomarkers and their correlation with disease severity. Timely supplementation of cholecalciferol has been demonstrated as one of the mortality reduction interventions. In recent studies, vitamin D has been identified as an important regulator of our immune system and its deficiency is quite common in ICU patients ranging from 81.5% to 99%.
A number of scientific studies have documented a strong correlation between low levels of vit.D and increased rate of adverse outcomes including infection with multi drug resistant organisms, acute kidney injury, decreased left ventricular ejection fraction and mortality in ICU patients. It has been found that the emergence of acinetobacter baumannii infections in significantly more common in vit D deficient critically ill patients and vit D deficiency is an independent risk factor for the development of Acinetobacter baumannii infections in intensive care unit.
A recent RCT has demonstrated 50% reduction in hospital mortality in patients with severe vit.D deficiency following a single high dose of cholecalciferol (Vitamin D3). However, the role of Vit.D supplementation to boost up host immune system and eventually reduction of mortality has yet to be determined by large randomized controlled trials.
In patients with severe vitamin D deficiency, gastrointestinal absorption of vit.D, after enteral supplementation could be variable depending upon the patient's gastrointestinal functions, critical illness and the activity of hepatic cytochrome P 450 system. In order to restore optimal vit.D level in critically ill patients (possibly within first 48 hours), a single high dose of it has been suggested on admission to ICU. As in critically ill patients, it is highly unlikely to restore Vitamin D within a reasonable period of time by supplementing 400-4000 international units/day (recommended daily allowance). Moreover, a single large dose of vit.D through the enteral route is highly unlikely to cause vit.D toxicity. The acutely toxic level of vit.D is considered to be more than 150 ng/ml. Furthermore, this high loading dose of cholecalciferol has been justified based on the safety findings of previous studies.
In addition, during a pilot study followed by a large randomized controlled trial conducted by Karen A et al, no serious adverse events were noted with a single high dose (540,000 I.U) of cholecalciferol. The highest 25-hydroxyvitamin D level measured was 107 ng/ml which is far below the currently suggested toxic level of vit.D (that is more than 150 ng/ml). Moreover, one patient in vitamin D3 group was found to have a total serum calcium level of 12 mg/dl and an ionized serum calcium level of 6 mg/dl but that patient had primary hyperparathyroidism (although normocalcemic at study inclusion). However, the incidence of falls and fracture was similar in vitamin D3 and placebo groups for a follow-up period of six months. So a single high dose of cholecalciferol is less likely to increase the incidence of hypocalcemia, hypercalciuria, falls and fractures which have been found to be increased with annual high doses of vitamin D3.
Hence the investigator intends to use a single high dose of cholecalciferol in order to restore it deficiency quickly, hopefully within 1 to 2 days in order to give maximum benefits to our critically ill patients right from the start of their illness.
The aim of our RCT is to study the role of Vit.D supplementation in critically ill patients. By boosting up the already struggling immune system of critically ill patients, the investigator assumes a significant reduction in mortality and other adverse outcomes.
Hypothesis: A single high dose of cholecalciferol supplementation improves survival in critically ill patients with severe vitamin D deficiency.
Null Hypothesis: A single high dose of Cholecalciferol supplementation in critically ill patients will not reduce the mortality and adverse outcomes.
Recruitment and randomization: Patients or their surrogates will be contacted on admission to ICU and study information will be provided to them by the research staff members. Consented patients will be randomized. Randomization list will be prepared by King Abdullah Medical City (KAMC) research center. The list will be used to prepare sealed envelopes each containing the assigned treatment. These envelopes will be stored in the pharmacy and opened up by the research pharmacist who will prepare medication/placebo for the randomized patients.
Blinding: Blinding will be done by research pharmacist in KAMC pharmacy. Fresh milk will be used as a placebo. The study medication (a white-colored, powdered form of cellulose based vit.D) will be dissolved in fresh milk so that both interventional drug and placebo will have the same color, odor, consistency, taste, and amount as that of interventional medication.
For all vit. D deficient patients, supplement 50,000 IU of cholecalciferol per week through the enteral route as a part of routine ICU treatment plan. As our recruited patients will be having severe vitamin D deficiency (Vit. D level below 12ng/ml) so both interventional and placebo group patients will receive our routine treatment for vit.D deficiency which is 50,000 IU of cholecalciferol through enteral route per week.
Intervention: Patients randomized to vitamin D group will receive 400,000 IU of cholecalciferol dissolved in 45 ml of fresh milk through orogastric tube/nasogastric tube/Oral within 1st 24 hours of ICU admission. This high dose is in addition to our routine treatment for vitamin D deficiency.
Post-recruitment retention strategies: the study will follow our patients for 30 days or as long as they stay in ICU after supplementation of a single high dose of vitamin D or placebo. As the investigators are working with critically ill patients, expecting at least a few weeks of hospital stay. However, the patient having early and quick recovery will be discharged home and will be followed up by one of the assigned research team members who will be contacting them by phone and inquire about any complications related to the research study.
Method: the investigator will complete a randomized controlled trial by supplementing cholecalciferol 400,000 IU versus placebo within 24 hours of ICU admission that would be added to our routine treatment for vit.D deficiency. Safety of this high dose of vit D has been validated in previous studies. This trial will employ block randomization and intention to treat protocol. This single-center study would be completed over a period of 2 complete years here in KAMC Intensive care Unit.
Laboratory Measurements: Blood samples will be obtained at baseline (day 0) and days 1, 3, 7, and 28 to assess serum parathyroid hormone, total and bioavailable 25-hydroxyvitamin D levels, phosphate, procalcitonin, leukocytic count, hemoglobin, creatinine, bilirubin, beta natriuretic peptide (BNP), blood glucose and albumin levels. In addition, the investigator will also measure urinary calcium and urinary creatinine levels
Data Collection: Patients will be followed up (1 month) closely for the development of study-drug related complications if any, for example, hypercalcemia, hypercalciuria, fractures, etc. Data elements to be collected will include, but not limited to:
1. \- Date and time of admission to hospital
2. \- Mode of admission (Emergency Room or in-patients)
3. \- Date and time of ICU admission
4. \- 25 - hydroxyl vitamin D level on admission to ICU.
5. \- Sequential Organ Failure Assessment (SOFA) score
6. \- Acute Physiology And Chronic Health Index (APACHI) Score 7-Patient's co-morbidities (Diabetes, Hypertension, Chronic kidney disease, Chronic obstructive pulmonary disease, Ischemic Heart Disease, Coronary Artery Bypass Grafting, Cerebrovascular accident, Arrhythmias, Anemias, smoking, obesity, cancer)
8 - Mode of Oxygen delivery to the patient 9 - Previous positive cultures and antibiotic therapy within the last 3 months 10 - Empirical antibiotic therapy on admission to hospital and ICU 11 - Baseline clinically relevant investigation, for example, Echo, Electrocardiography, Ultrasound Doppler for Deep venous thrombosis, CT brain/chest/abdomen, 12 - Endo/bronchoscopic findings if any 13 - Vasopressors and ionotropic support duration 14 - Central venous catheter, arterial line, pigtail, chest tube (site, date and time of insertion) 15 - Evidence of acute or acute on chronic kidney injury on admission to ICU. 16 - Surgeries - previous and recent surgeries and any post-op complications 17 - Previous immunosuppressive therapies for example chemo/radio/glucocorticoid therapy.
Sample size calculation: A recent RCT demonstrated almost 50% reduction in hospital mortality (46.1% in placebo versus 28.6% in Vit D group) by supplementing 540,000 IU of Vit D3 to critically ill patients having severe vitamin D deficiency (25-hydroxyvitamin D level ≤ 12 ng/ml). With an alpha = 5% (two tailed test), power = 95%, baseline mortality control group 30% and test group mortality 15%, the sample size required would be 195 patients per group. To account for losses to follow up of around 10%, the study aims to recruit 215 patients in each group. So the total number of patients required for both the groups would be 430 in 2 full years.
Statistical Analysis: the investigator will use an intention to treat approach to avoid the effects of crossover and dropout. Standard statistical analysis will include normally or near normally distributed variables reported as means and non-normally distributed variables as medians. Means will be compared by using student's t-test and medians by using Mann-Whitney U test. Differences in proportions among categorical data will be assessed using Fisher's exact test. A p-value of less than 0.05 will be considered to represent statistical significance for all comparisons.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Vitamin D Deficiency
Critical Illness
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cholecalciferol
This group of patients will receive single high dose of vitamin D (Cholecalciferol) dissolved in 45 ml of fresh milk (Nestle)
Group Type
EXPERIMENTAL
Cholecalciferol
Intervention Type
DRUG
400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
Placebo
This group of patients will receive placebo - 45 ml of fresh milk (Nestle) so that the amount, color, smell, taste etc will be the same as that of experimental drug)
Group Type
PLACEBO_COMPARATOR
Milk (Nestle)
Intervention Type
OTHER
45 ml of Nestle milk will given to patients assigned as placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cholecalciferol
400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
Intervention Type
DRUG
Milk (Nestle)
45 ml of Nestle milk will given to patients assigned as placebo
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Vitamin D3
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. 18 years or older.
2. Both male and female
3. Within 24 hours from admission.
4. Having 25 -Hydroxyvitamin D level of 12 ng/ml or lower.
2. Both male and female
3. Within 24 hours from admission.
4. Having 25 -Hydroxyvitamin D level of 12 ng/ml or lower.
Exclusion Criteria
1. Pregnant or lactating females.
2. Do not resuscitate (DNR) status or comfort measures only
3. No consent
4. Severely impaired gastrointestinal functions (e.g, paralytic ileus, continuous nasogastric tube drainage, strict nil per oral- no medication, malabsorption syndrome, chronic diarrhea etc)
5. History of renal stones within past year
6. Past history of hypercalcemia, tuberculosis or sarcoidosis.
7. Baseline serum total calcium ≥10.6 mg/dl or ionized serum calcium ≥ 5.4 mg/dl.
2. Do not resuscitate (DNR) status or comfort measures only
3. No consent
4. Severely impaired gastrointestinal functions (e.g, paralytic ileus, continuous nasogastric tube drainage, strict nil per oral- no medication, malabsorption syndrome, chronic diarrhea etc)
5. History of renal stones within past year
6. Past history of hypercalcemia, tuberculosis or sarcoidosis.
7. Baseline serum total calcium ≥10.6 mg/dl or ionized serum calcium ≥ 5.4 mg/dl.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King Abdullah Medical City
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asiah Rugaan
Consultant and Head of Department - Intensive Care Unit
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Asiah S Rugaan, MD, MRCP
Role: STUDY_CHAIR
King Abdullah Medical City Makkah
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King Abdullah Medical City, Holy Capital
Mecca, Makkah Western, Saudi Arabia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Saudi Arabia
References
Explore related publications, articles, or registry entries linked to this study.
Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients. Inflamm Allergy Drug Targets. 2013 Aug;12(4):273-81. doi: 10.2174/18715281113129990047.
Reference Type
BACKGROUND
Quraishi SA, De Pascale G, Needleman JS, Nakazawa H, Kaneki M, Bajwa EK, Camargo CA Jr, Bhan I. Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial. Crit Care Med. 2015 Sep;43(9):1928-37. doi: 10.1097/CCM.0000000000001148.
Reference Type
BACKGROUND
Higgins DM, Wischmeyer PE, Queensland KM, Sillau SH, Sufit AJ, Heyland DK. Relationship of vitamin D deficiency to clinical outcomes in critically ill patients. JPEN J Parenter Enteral Nutr. 2012 Nov;36(6):713-20. doi: 10.1177/0148607112444449. Epub 2012 Apr 20.
Reference Type
BACKGROUND
Lee P, Eisman JA, Center JR. Vitamin D deficiency in critically ill patients. N Engl J Med. 2009 Apr 30;360(18):1912-4. doi: 10.1056/NEJMc0809996. No abstract available.
Reference Type
BACKGROUND
Matthews LR, Ahmed Y, Wilson KL, Griggs DD, Danner OK. Worsening severity of vitamin D deficiency is associated with increased length of stay, surgical intensive care unit cost, and mortality rate in surgical intensive care unit patients. Am J Surg. 2012 Jul;204(1):37-43. doi: 10.1016/j.amjsurg.2011.07.021. Epub 2012 Feb 10.
Reference Type
BACKGROUND
Braun A, Chang D, Mahadevappa K, Gibbons FK, Liu Y, Giovannucci E, Christopher KB. Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. Crit Care Med. 2011 Apr;39(4):671-7. doi: 10.1097/CCM.0b013e318206ccdf.
Reference Type
BACKGROUND
Braun AB, Litonjua AA, Moromizato T, Gibbons FK, Giovannucci E, Christopher KB. Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill. Crit Care Med. 2012 Dec;40(12):3170-9. doi: 10.1097/CCM.0b013e318260c928.
Reference Type
BACKGROUND
Arnson Y, Gringauz I, Itzhaky D, Amital H. Vitamin D deficiency is associated with poor outcomes and increased mortality in severely ill patients. QJM. 2012 Jul;105(7):633-9. doi: 10.1093/qjmed/hcs014. Epub 2012 Feb 12.
Reference Type
BACKGROUND
Braun AB, Gibbons FK, Litonjua AA, Giovannucci E, Christopher KB. Low serum 25-hydroxyvitamin D at critical care initiation is associated with increased mortality. Crit Care Med. 2012 Jan;40(1):63-72. doi: 10.1097/CCM.0b013e31822d74f3.
Reference Type
BACKGROUND
Turkoglu M, Aygencel G, Dizbay M, Tuncel AF, Arslan Candir B, Deligoz Bildaci Y, Pasaoglu H. Is vitamin D deficiency associated with development of Acinetobacter baumannii infections in critically ill patients? J Crit Care. 2013 Oct;28(5):735-40. doi: 10.1016/j.jcrc.2013.03.017.
Reference Type
BACKGROUND
Amrein K, Schnedl C, Holl A, Riedl R, Christopher KB, Pachler C, Urbanic Purkart T, Waltensdorfer A, Munch A, Warnkross H, Stojakovic T, Bisping E, Toller W, Smolle KH, Berghold A, Pieber TR, Dobnig H. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA. 2014 Oct 15;312(15):1520-30. doi: 10.1001/jama.2014.13204.
Reference Type
BACKGROUND
Spriet I, Meersseman W, de Hoon J, von Winckelmann S, Wilmer A, Willems L. Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med. 2009 Apr;35(4):603-12. doi: 10.1007/s00134-008-1383-2. Epub 2009 Jan 9.
Reference Type
BACKGROUND
Michaud J, Naud J, Ouimet D, Demers C, Petit JL, Leblond FA, Bonnardeaux A, Gascon-Barre M, Pichette V. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol. 2010 Sep;21(9):1488-97. doi: 10.1681/ASN.2009080815. Epub 2010 Jul 1.
Reference Type
BACKGROUND
McNally JD. Vitamin D as a modifiable risk factor in critical illness: questions and answers provided by observational studies. J Pediatr (Rio J). 2014 Mar-Apr;90(2):99-101. doi: 10.1016/j.jped.2013.12.002. Epub 2013 Dec 19. No abstract available.
Reference Type
BACKGROUND
Amrein K, Sourij H, Wagner G, Holl A, Pieber TR, Smolle KH, Stojakovic T, Schnedl C, Dobnig H. Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study. Crit Care. 2011;15(2):R104. doi: 10.1186/cc10120. Epub 2011 Mar 28.
Reference Type
BACKGROUND
Bacon CJ, Gamble GD, Horne AM, Scott MA, Reid IR. High-dose oral vitamin D3 supplementation in the elderly. Osteoporos Int. 2009 Aug;20(8):1407-15. doi: 10.1007/s00198-008-0814-9. Epub 2008 Dec 20.
Reference Type
BACKGROUND
von Restorff C, Bischoff-Ferrari HA, Theiler R. High-dose oral vitamin D3 supplementation in rheumatology patients with severe vitamin D3 deficiency. Bone. 2009 Oct;45(4):747-9. doi: 10.1016/j.bone.2009.06.012. Epub 2009 Jun 17.
Reference Type
BACKGROUND
Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. doi: 10.1056/NEJMra070553. No abstract available.
Reference Type
BACKGROUND
Vieth R. Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J Nutr. 2006 Apr;136(4):1117-22. doi: 10.1093/jn/136.4.1117.
Reference Type
BACKGROUND
Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010 May 12;303(18):1815-22. doi: 10.1001/jama.2010.594.
Reference Type
BACKGROUND
Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2007 Dec;46(12):1852-7. doi: 10.1093/rheumatology/kem240. Epub 2007 Nov 12.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-252
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Early Vitamin D3 Supplementation for Critically Ill Patients
NCT05937789
RECRUITING
NA
Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels
NCT01170494
COMPLETED
NA
Prevalence of Deficiency of Vitamin D in Critically Ill Patients
NCT03639584
COMPLETED
Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation
NCT01079923
COMPLETED
NA
Effects of Cholecalciferol Supplementation on Bone Health and Muscle Strength in Adults During Post-burn Period
NCT02092701
COMPLETED
NA
High-Dose Vitamin D Deficiency in Burn Injury
NCT00591604
WITHDRAWN
PHASE3
Vitamin D Deficiency in Adults Following a Major Burn Injury
NCT05084248
COMPLETED
PHASE4
Cholecalciferol Supplementation, Muscle Strength
NCT00682214
COMPLETED
PHASE1
Vitamin D and Critically Ill Patients
NCT01636232
COMPLETED
Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults
NCT03228862
UNKNOWN
PHASE4
Trial to Assess Vitamin D Requirements in Lactating Women
NCT01349127
COMPLETED
NA
Clinical Approaches to Correcting Vitamin D Inadequacy and Maintaining Adequacy
NCT00692120
COMPLETED
NA
Vitamin D Administration in the Nursing Home
NCT00204919
COMPLETED
NA
Serum Vitamin D Levels in Critically Ill Patients Undergoing Regional Citrate Anticoagulation CRRT
NCT02414386
COMPLETED
Interventional Trial of Vitamin D Deficiency in the Patients of General Departments
NCT00640237
UNKNOWN
PHASE3
High Dose Vitamin D Replacement in Patients Undergoing Hematopoietic Stem Cell Transplantation
NCT02876822
TERMINATED
NA
Vitamin D in Ventilated ICU Patients
NCT01372995
COMPLETED
PHASE2
Vitamin D3 Supplementation in Critically Ill Patients Undergoing CRRT
NCT05657678
RECRUITING
PHASE4
Vitamin D and Muscle Strength and Surface (Electromyography) EMG
NCT01190683
COMPLETED
PHASE3
Treatment of Vitamin D Deficiency With Large Bolus Cholecalciferol
NCT04120064
TERMINATED
PHASE1
Does Correction of 25 OH-VITAmin D With Cholecalciferol Supplementation Increase Muscle Strength in hemoDIALysis Patients?
NCT04262934
UNKNOWN
PHASE3
Treatment of Vitamin D Insufficiency
NCT00933244
COMPLETED
PHASE4
Vitamin D for Critically Traumatic Patients
NCT05449522
RECRUITING
NA
Rapid Normalization of Vitamin D Deficiency in PICU
NCT03742505
COMPLETED
PHASE3
Cholecalciferol Supplementation for Sepsis in the ICU
NCT01896544
COMPLETED
PHASE3